6505--Specialty Pharmaceutical Lenalidomide FAR Part 8 FSS - LPTA
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA) has awarded EXELAN PHARMACEUTICALS INC a contract for Specialty Pharmaceutical Lenalidomide for the Wilkes-Barre facility. This award, valued at $1,548,123.77, was made on February 6, 2026, specifically for Lenalidomide 5MG oral capsules. The original solicitation was conducted under FAR Part 8 FSS and utilized a Lowest Price Technically Acceptable (LPTA) evaluation approach.
Scope of Work
The awarded contract covers the procurement of 1,358 units of Lenalidomide 5MG oral capsules. The original requirement, as outlined in the solicitation, also included various other strengths of Lenalidomide oral capsules, such as 10MG, 15MG, 2.5MG, 25MG, and 20MG.
Contract & Timeline
- Awardee: EXELAN PHARMACEUTICALS INC
- Value: $1,548,123.77 (for Line Item 6: Lenalidomide 5MG CAP, ORAL)
- Award Date: February 6, 2026
- Contract Period: Base year from January 30, 2026, to January 29, 2027
- NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing
- Product Service Code: 6505 - Drugs and Biologicals
- Set-Aside: Not specified
Evaluation
The original solicitation indicated that award would be based on a Lowest Price Technically Acceptable (LPTA) methodology.
Contact
For further information regarding this award, contact Ryan Hatfield, Contract Specialist, at Ryan.Hatfield@va.gov or 412-641-0409.